Clinical Trial Update: Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Sintilimab plus nab-paclitaxel as second-line therapy for advanced gastric and gastro-esophageal junction adenocarcinoma; status not di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Sintilimab (sintilimab)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma | Phase 2 | Status: UNKNOWN